Sentinel Lymph Node Biopsy (SLNBx) for intermediate thickness Melanoma

This page provides for a new item added to the MBS for sentinel lymph node biopsy services for Melanoma patients from 1 November 2021.

Page last updated: 25 October 2021

From 1 November 2021, there will be a revised structure for items for sentinel lymph node biopsy or biopsies (SLNBx) for cutaneous with intermediate thickness melanoma (≥ 1.0 mm Breslow thickness, or those ≥0.8mm with high-risk features).

The Australian Government is making changes to Medicare-funded services to support high-value care and ensure patients with intermediate thickness Melanoma have access to the most appropriate diagnostic tests to determine if cancer has spread into the nearby lymph nodes.

PDF version Sentinel Lymph Node Biopsy for Intermediate Thickness Melanoma (PDF 224 KB)
Word version Sentinel Lymph Node Biopsy for Intermediate Thickness Melanoma (Word 83 KB)

In this section